Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2015-002354-12-IT
EUCTR2015-002354-12-IT
Active, not recruiting
Phase 1

A phase I-Ib/II, open-label, multi-center study of the safety and efficacy of MBG453 as single agent and in combination with PDR001 in adult patients with advanced malignancies - An interventional study of MBG453 alone and in combination with PDR001 in patients with advanced mal

OVARTIS FARMA S.P.A.0 sites250 target enrollmentStarted: August 20, 2018Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsSolid tumorsMedDRA version: 20.0Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: PTClassification code 10073251Term: Clear cell renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10029111Term: Neoplasms unspecified malignancy and site unspecified NECSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]

Overview

Phase
Phase 1
Status
Active, not recruiting
Sponsor
OVARTIS FARMA S.P.A.
Enrollment
250
OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •1\. Histologically documented advanced or metastatic solid tumors.
  • •2\. Phase I\-Ib part (including dose ranging part): Patients with advanced/metastatic solid tumors, with measurable or non\-measurable disease as determined by RECIST v1\.1, who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists and who did not receive prior anti\-PD1/PD\-L1 treatment.
  • •3\. Phase II part (MBG453 single agent): Patients with advanced/metastatic solid tumors in the indication in which at least one confirmed PR or CR was seen during the dose escalation phase I part. Patients must have measurable disease as determined by RECIST v1\.1, have progressed despite standard therapy or be intolerant to standard therapy.
  • •4\. Phase II part (MBG453 in combination PDR001\): Patients with advanced/metastatic tumors in the below selected indications, with at least one measurable lesion as determined by RECIST v1\.1, who have received standard therapy and are intolerant of standard therapy or have progressed following their last prior therapy.:
  • •Melanoma (anti\-PD\-1/PD\-L1 therapy naïve or pre\-treated)
  • •NSCLC (anti\-PD\-1/PD\-L1 therapy naïve or pre\-treated)
  • •RCC (anti\-PD\-1/PD\-L1 therapy naïve or pre\-treated)
  • •5\. Must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy according to the treating institution’s guidelines. Patient must be willing to undergo a new tumor biopsy at screening/baseline, and during therapy on the study.
  • •Other protocol\-defined inclusion criteria may apply.
  • •Are the trial subjects under 18? no

Exclusion Criteria

  • •1\. Presence of symptomatic central nervous system (CNS) metastases.
  • •2\. History of severe hypersensitivity reactions to other monoclonal antibodies (mAbs).
  • •3\. Human Immunodeficiency Virus (HIV), HBV (Hepatitis B Virus) or HCV (Hepatitis C Virus) infection.
  • •4\. Active autoimmune disease or a documented history of autoimmune disease, including ulcerative colitis and Crohn’s disease or any condition that requires systemic steroids.
  • •5\. Systemic steroid therapy or any immunosuppressive therapy (\=10mg/day prednisone or equivalent).
  • •6\. Use of any vaccines against infectious diseases (e.g. varicella, pneumococcus) within 4 weeks of initiation of study treatment.
  • •7\. Pre\-treatment with anti\-CTLA4 antibodies in combination with any other antibody or drug specifically targeting T\-cell co\-stimulation or checkpoint pathway.
  • •8\. Participation in an interventional, investigational non\-immunotherapy study within 2 weeks of the first dose of study treatment.
  • •9\. Prior participation in an interventional, investigational cancer vaccine or immunotherapy study except for an anti\-PD\-1/PD\-L1 study.
  • •Other protocol\-defined exclusion criteria may apply.

Investigators

Sponsor
OVARTIS FARMA S.P.A.

Similar Trials

Completed
Not Applicable
A phase I-Ib/II, open-label, multi-center study of the safety and efficacy of MBG453 as single agent and in combination with PDR001 in adult patients with advanced malignanciesadvanced cancerlungcancermelanoma10027655
NL-OMON53097ovartis33
Active, not recruiting
Phase 1
An interventional study of MBG453 as single agent and in combination with PDR001 in patients with advanced malignanciesSolid tumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2015-002354-12-NLovartis Pharma Services AG252
Active, not recruiting
Phase 1
An interventional study of MBG453 alone and in combination with PDR001 in patients with advanced malignanciesSolid tumorsTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2015-002354-12-DEovartis Pharma Services AG250
Completed
Phase 1
Phase I-Ib/II study of MBG453 as single agent and in combination with PDR001 in patients with advanced malignancies.advanced solid tumor
JPRN-jRCT2080223302ovartis Pharma. K.K.21
Active, not recruiting
Phase 1
A phase Ib/IIb, open-label, multi-center study of oral Panobinostat (LBH589) administered with 5-Azacitidine (Vidaza®) in adult patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML) - N/AMyelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML)MedDRA version: 19.0 Level: LLT Classification code 10000886 Term: Acute myeloid leukemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0 Level: PT Classification code 10009018 Term: Chronic myelomonocytic leukaemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0 Level: PT Classification code 10028533 Term: Myelodysplastic syndrome System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2009-010548-32-SEovartis Pharma Services AG119